Sven Arnouts Email & Phone Number

Bertem, Be

Ghent, Flemish Region, Belgium

The DIAH Conference brings together early developers and companies to stimulate innovation!The pivotal role of the conference is to bridge the gap between early developers, including academia, research organizations, and spin-offs/start-ups, and medium- to large-sized companies. It aims to enhance industry's access to cutting-edge technologies and expertise while familiarizing researchers with the innovation pipeline, product development stages, intellectual property (IP), and regulatory frameworks.DIAH differentiates from B2B conferences and focuses on innovation in animal health through collaboration in the phase of pre-development / discovery / proof-of-concept: Discovery to Innovation in Animal Health (DIAH).

As Business Developer I coordinate the activities of PROVAXS (www.provaxs.com) and organize the follow up of its valorisation projects.PROVAXS is the coordinating center of a network of laboratories of the University of Ghent that unite their expertise in the development of veterinary and human vaccines, therapeutics and diagnostics.PROVAXS focuses on those projects and research results that respond to an urgent need in society or in the market and can lead to industrial applications. I coordinate the protection and licensing of our intellectual property and build strategic alliances for its valorisation.PROVAXS offers a multidisciplinary environment for research and development directed towards technologies with practical applications in industryPROVAXS can be your gateway to participation in a network of high-quality R&D in various research programs at national and international level

As Technology Developer I started the activities of PROVAXS (www.provaxs.com) and organized the follow up of its valorisation projects.PROVAXS is the coordinating center of a network of laboratories of the University of Ghent that unite their expertise in the development of veterinary and human vaccines, therapeutics and diagnostics.PROVAXS focuses on those projects and research results that respond to an urgent need in society or in the market and can lead to industrial applications. I coordinate the protection and licensing of our intellectual property and build strategic alliances for its valorisation.PROVAXS offers a multidisciplinary environment for research and development directed towards technologies with practical applications in industryPROVAXS can be your gateway to participation in a network of high-quality R&D in various research programs at national and international level

Http://Flandersvaccine.Be/About-Us/

Flanders Vaccine is a non-profit, strategy-driven platform for academic, industrial and public stakeholders with relevant expertise in human and animal immunotherapeutics and vaccines. Flanders Vaccine brings together universities, public and private hospitals, research centres, SMEs, pharma, competence providers, patient organisations, and government bodies to develop novel immunological health solutions and the vaccines of the future.Flanders Vaccine supports the development of immunotherapeutics and vaccines for both prophylactic and therapeutic targets in humans and animals by facilitating the exchange of know-how and complementary innovative technologies between academia and industry. The Flanders vaccine platform can be seen as an integrated tool that gives rise to more and better partnerships; that prepares us better for future calls for funding; that enables us to network at inspiring meetings and conferences; that generates visibility and attracts significant attention from national and international experts, stakeholders and organisations.

STAR-IDAZ IRC has set for itself the ambitious goals to deliver improved control tools/strategies, including candidate vaccines, diagnostics, therapeutics and other animal health products and procedures and/or key scientific information/tools to support risk analysis and disease control for at least 30 priority diseases by 2022.The IRC Executive Committee is composed of one representative per funding body (including public funding bodies, charities and the animal health industry), or group of funders, OIE, the Chair of the Scientific Committee and the STAR-IDAZ Chairperson.The STAR-IDAZ IRC Executive Committee:• Agrees and adopts STAR-IDAZ IRC Governance, Policies and Guidelines, including decisions on the creation or closure of Working Groups• Coordinates research funding strategies to address identified research priorities such as those identified by the Scientific Committee• Advocacy – promotes support for STAR-IDAZ IRC objectives from the livestock and animal health industries and services and the wider donor community.• Monitors progress and provides updates to funding bodies.• Reviews nominations and accepts new members to the Scientific Committee• Agrees on a Communication Strategy that ensures timely and correct dissemination regarding STAR-IDAZ IRC objectives and progress made• Provides a forum for the resolution of any conflicts, should they arise.Members of the Executive Committee may participate in meetings of any Working Group.

Biocheck.UGent is a scientific risk-based and independent scoring system to evaluate the quality of your on-farm biosecurity.

TRANSVAC2 builds upon the success of TRANSVAC, the European Network of Vaccine Research and Development funded under the EC´s previous Framework Programme (FP7). TRANSVAC made significant contributions to the European vaccine development landscape, providing scientific-technical services to more than 29 vaccine projects and developing a roadmap for the establishment of a sustainable European vaccine R&D.TRANSVAC2 will support innovation for both prophylactic and therapeutic vaccine development. High-quality technical services across four different service platforms will be offered: Technology (for process development and GMP production), Immunocorrelates & Systems Biology, Animal models, and support for Clinical Trials. Researchers, including those from industry, can apply to benefit from the expertise, reagents, and facilities offered by TRANSVAC2 to accelerate the development of their vaccines.

From 1994 to 2006 I was global R&D Manager Agriculture at INVE where I was responsible for research activities in animal nutrition for pigs, poultry and ruminants with a special focus on the relation between nutrition and health.

At the University of Leuven I did my PhD on an industrial project in collaboration with Solvay-Duphar (Immunoneutralisation of somatostatin and the effect on performance of broilers and broiler breeders).

Tech Transfer Officer, Technology Transfer

Phd, Immunology, Physiology, Vaccination, Animal Breeding

Master, Animal Production & Cell- And Genetechnology

Education record

Education record